CLENE INC. news, videos and press releases - Page 3
For more news please use our advanced search feature.
CLENE INC. - More news...
CLENE INC. - More news...
- Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg
- Clene Announces Closing of $5 Million Debt Facility from the State of Maryland
- VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies
- Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
- Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial
- Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3
- Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference
- Clene to Present at Upcoming September Investor Conferences
- Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights
- Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis
- Clene to Host VISIONARY-MS Results Call and Webcast on August 15
- Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS
- Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial
- Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28
- Clene Salutes Collaboration of ALS Community and Major League Baseball on Lou Gehrig Day
- New Data from Clene’s RESCUE-ALS Study to be Presented at 2022 ENCALS Meeting
- Clene Receives $3 Million Loan from State of Maryland to Support Development of Commercial Manufacturing Facility
- Clene to Present at Upcoming Investor Conferences
- Clene Reports First Quarter 2022 Financial Results and Recent Operating Highlights
- Updated Interim Data from Clene Nanomedicine’s RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Science Program at 2022 AAN Annual Meeting
- Clene Nanomedicine Presents Updated Clinical Data from Phase 2 RESCUE-ALS and REPAIR trials and Preclinical ALS data at 2022 MDA Clinical & Scientific Conference
- Clene Reports Full Year 2021 Financial Results and Recent Operating Highlights
- Clene Nanomedicine to Present at Upcoming Investor Conferences
- Clene Nanomedicine Presents Data from Two Phase 2 Multiple Sclerosis Trials at ACTRIMS Forum 2022
- Clene Nanomedicine to Present Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2022
- Clene Nanomedicine Provides Clinical Program Update
- Clene Announces New Chief Financial Officer Morgan Brown
- Clene Nanomedicine’s Second Asset, CNM-ZnAg, Completes 50% Patient Enrollment in COVID-19 Trial
